Purpose: This study aimed to evaluate the choroidal vascularity index (CVI) as an activity criterion in chronic central serous chorioretinopathy (CSC) and as a measure of treatment response after full-dose-full-fluence photodynamic therapy (fd-ff-PDT).

Methods: This fellow-eye-controlled, retrospective cohort study included 23 patients with unilateral chronic CSC treated with fd-ff-PDT (6 mg/m ; 50 μcm ; 83 s). Subfoveal choroidal thickness (SFCT, μm) and CVI (%) of the affected and fellow eyes at baseline as well as at 1, 3 and 6 months after fd-ff-PDT were compared.

Results: The patients' mean age was 43.4 ± 7.3 years, and 18 (78.3%) were male. CVI was comparable between the affected and fellow eyes at baseline (66.09 ± 1.56 vs. 65.84 ± 1.57, p = 0.59). However, it became significantly lower in the affected eyes 1 (64.45 ± 1.68 vs. 65.87 ± 1.19, p = 0.002), 3 (64.21 ± 2.08 vs. 65.71 ± 1.59, p = 0.009) and 6 (64.47 ± 2.19 vs. 65.62 ± 1.52, p = 0.045) months after fd-ff-PDT. The mean SFCT and the mean CVI were significantly decreased in the affected eyes at all follow-up visits compared with baseline after fd-ff-PDT (p < 0.001).

Conclusion: At baseline, CVI was comparable between affected and fellow eyes. Therefore, its use as an activity criterion in chronic CSC patients is questionable. However, it was significantly decreased in fd-ff-PDT-treated eyes, supporting its role as a measure of treatment response in chronic CSC.

Download full-text PDF

Source
http://dx.doi.org/10.1111/opo.13187DOI Listing

Publication Analysis

Top Keywords

choroidal vascularity
8
activity criterion
8
treatment response
8
chronic central
8
central serous
8
serous chorioretinopathy
8
fellow eyes
8
eyes baseline
8
vascularity activity
4
criterion treatment
4

Similar Publications

Comment on: Subretinal Gene Therapy for Treatment of Retinal and Choroidal Vascular Diseases.

Am J Ophthalmol

January 2025

PharmaLogic Development, Inc., San Rafael CA; Department of Ophthalmology & Vision Science, University of California, Davis, School of Medicine. Electronic address:

View Article and Find Full Text PDF

The Northern Lights Neuroscience Symposium 2024 "Expanding Spectrum of Common Dementia Disorders" was held in Hanasaari, Helsinki (Espoo), Finland on September 26-27, 2024. The meeting was jointly organised by the Scandinavian Neuropathological Society (chair Olivera Casar-Borota) and University of Helsinki. Drs.

View Article and Find Full Text PDF

The choroid, a critical vascular layer beneath the retina, is essential for maintaining retinal function and monitoring chorioretinal disorders. Existing imaging methods, such as indocyanine green angiography (ICGA) and optical coherence tomography (OCT), face significant limitations, including contrast agent requirements, restricted field of view (FOV), and high costs, limiting accessibility. To address these challenges, we developed a nonmydriatic, contrast agent-free fundus camera utilizing transcranial near-infrared (NIR) illumination.

View Article and Find Full Text PDF

Choroid plexus-targeted viral gene therapy for alpha-mannosidosis, a prototypical neurometabolic lysosomal storage disease.

Hum Mol Genet

January 2025

Section on Translational Neuroscience, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.

The choroid plexuses (CP) are highly vascularized structures that project into the ventricles of the vertebrate brain. The polarized epithelia of the CP produce cerebrospinal fluid by transporting water and ions into the ventricles from the blood and normally secrete a large number of proteins. We assessed the feasibility of selective CP transduction with recombinant adeno-associated virus (rAAV) gene therapy vectors for treatment of lysosomal storage disease (LSD), a broad category of neurometabolic illness associated with significant burdens to affected patients and their families.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!